一个无的II/III期设计,用于瘤学药物开发的剂量优化
Yuhan Li1, Yiding Zhang2, Gu Mi2
1Department of Statistics, University of Illinois Urbana-Champaign, Champaign, Illinois, USA.
Statistics in medicine
|June 7, 2024
概括
这项研究引入了瘤药物试验的新无设计,在营销批准之前优化剂量. 这种方法提高了效率和灵活性,同时确保了可靠的剂量选择和统计能力.
科学领域:
- 瘤学 药物开发 药物开发
- 临床试验设计 临床试验设计
- 监管科学 监管科学
背景情况:
- 美国食品和药物管理局 (FDA) 的Project Optimus倡议促进在营销批准之前优化剂量.
- 传统的关键试验设计需要调整以整合剂量优化组件.
- 重新思考试验方法对于与瘤学的新监管期望保持一致至关重要.
研究的目的:
- 提出一种新的无II/III阶段设计与剂量优化 (SDDO框架).
- 为了在随机试验环境中促进剂量优化.
- 在统一的试验结构中支持加速批准 (AA) 和定期批准的监管途径.
主要方法:
- 一个无的II/III阶段设计,包括初始剂量优化阶段.
- 随机剂量优化,然后进行剂量选择和样本大小重新估计 (SSR) 的中间分析.
- 根据临时分析决定继续招募患者,最终分析确定治疗效果的意义.
主要成果:
- SDDO框架允许灵活且成本效益高的样本大小调整.
- 该设计严格控制I型错误,同时保持统计能力.
- 广泛的模拟证实了可靠的最佳剂量识别和在较小的样本大小下优选的决策.
结论:
- 拟议的SDDO框架有效地将剂量优化纳入II/III期瘤学试验.
- 这种创新设计提高了试验效率,成本效益和监管灵活性.
- SDDO框架支持药物批准的简化"一次性试验"方法,达到 Project Optimus 的目标.
更多相关视频
相关概念视频
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Drug Discovery: Overview
7.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.8K
Drug Administration and Therapy Phases: Overview
448
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
448
Preclinical Development: Overview
4.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.4K
Nonlinear Pharmacokinetics: Overview
352
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Nonlinearity can arise due to the saturation of plasma protein-binding or...
352
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


